Arava Side Effects
Generic name: leflunomide
Note: This document contains side effect information about leflunomide. Some of the dosage forms listed on this page may not apply to the brand name Arava.
Some side effects of Arava may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.
For the Consumer
Applies to leflunomide: oral tablet
Get emergency medical help if you have any of these signs of an allergic reaction while taking leflunomide (the active ingredient contained in Arava) hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Stop using leflunomide and call your doctor at once if you have any of these serious side effects:
fever, chills, body aches, flu symptoms;
white patches or sores inside your mouth or on your lips;
chest pain, dry cough, wheezing, feeling short of breath (you may also have a fever);
pain or burning when you urinate;
pale skin, easy bruising or bleeding, unusual weakness;
nausea, stomach pain, loss of appetite, itching, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes); or
fever, sore throat, and headache with a severe blistering, peeling, and red skin rash.
Less serious side effects of leflunomide may include:
mild stomach pain, diarrhea, loss of appetite;
numbness or tingling;
runny or stuffy nose, cold symptoms; or
mild itching or skin rash.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects.
For Healthcare Professionals
Applies to leflunomide: oral tablet
Gastrointestinal side effects have included diarrhea (17%), nausea (9%), gastrointestinal pain (5% or greater), abdominal pain (5%), dyspepsia (5%), anorexia (3%), vomiting (3%), and mouth ulcer (3%). Cholelithiasis, colitis, constipation, esophagitis, flatulence, gastroenteritis, gingivitis, melena, oral moniliasis, pharyngitis, enlarged salivary gland, stomatitis (or aphthous stomatitis), and tooth disorder have been reported. Pancreatitis has been reported rarely in postmarketing experience. At least one case of parastomal collection and stomach perforation has been reported.
A 58-year-old female with longstanding rheumatoid arthritis experienced parastomal collection and stomach perforation coincident with leflunomide therapy. The patient had been taking leflunomide 20 mg per day and prednisone 5 mg per day. She presented with complaints of a one day history of abdominal pain. A CT scan showed a parastomal collection and stomach perforation. She proceeded to surgery for drainage of the collection and repair of the perforation. The leflunomide therapy was subsequently stopped and cholestyramine washout administered. She required prolonged hospital stay, with total parenteral nutrition and intravenous antibiotics.
A 54-year-old female with rheumatoid arthritis experienced acute respiratory failure coincident with leflunomide (the active ingredient contained in Arava) therapy. She developed the adverse event 2 weeks after cessation of 6-weeks treatment with leflunomide. She was diagnosed with interstitial pneumonia, probably induced by leflunomide because acute respiratory failure was preceded by hypertension and elevated serum liver enzyme concentration. She showed dramatic improvement with cholestyramine and prednisolone.
Respiratory side effects have included respiratory infection (15%), bronchitis (7%), increased cough (3%), pharyngitis (3%), pneumonia (2%), rhinitis (2%), and sinusitis (2%). Asthma, dyspnea, epistaxis, and interstitial lung disease, with fatal outcomes, have been reported. At least one case of acute interstitial pneumonia has also been reported, in addition to a case of infected lung bullae, and a case of pulmonary tuberculosis.
Cardiovascular side effects have included hypertension (10%) and chest pain (2%). Angina pectoris, migraine, palpitation, tachycardia, vasculitis, vasodilation, and varicose veins have been reported. Angioedema has also been reported rarely in postmarketing experience.
A 46-year-old woman with erosive and refractory rheumatoid arthritis (RA) developed sudden focal hair loss (alopecia areata) after 3 weeks of treatment with leflunomide (the active ingredient contained in Arava) Three months after leflunomide had been stopped due to poor control of RA, the patient's hair was slowly recovering.
A 61-year-old female with severe rheumatoid arthritis experienced cellulitis coincident with leflunomide therapy. The patient had been taking leflunomide 20 mg alternate days and prednisone 10 mg per day. She presented with cellulitis of the left foot that had not responded to oral amoxicillin/clavulanic acid. Isolates from a plantar ulcer showed Staphylococcus aureus. Despite appropriate antibiotic treatment, the infection progressed rapidly and she developed necrosis of the left foot. She proceeded to surgical debridement with forefoot amputation and skin graft. On day 4 of admission, leflunomide therapy was discontinued and cholestyramine washout administered. She had a prolonged hospital stay that required 5 further debridement procedures.
Dermatologic side effects have included rash (10% or greater), alopecia (10%), pruritus (4% or greater), eczema (2%), and dry skin (2%). Acne, contact dermatitis, fungal dermatitis, hair discoloration, hematoma, herpes simplex, herpes zoster, nail disorder, skin nodule, subcutaneous nodule, macropapular rash, skin disorder, skin discoloration, urticaria, and skin ulcer have been reported. At least one case of alopecia areata has also been reported. At least one case of cellulitis has also been reported, in addition to a case of cellulitis with local necrosis. Post marketing reports of erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, vasculitis including cutaneous necrotizing vasculitis, cutaneous lupus erythematosus, pustular psoriasis or worsening psoriasis have been received.
Nervous system side effects have included headache (7%), dizziness (4%), paresthesia (2%), and pain (2%). Back pain, neck pain, pelvic pain, anxiety, depression, dry mouth, insomnia, neuralgia, neuritis, sleep disorder, sweat, and vertigo have been reported. Peripheral neuropathy has also been reported rarely in postmarketing experience.
Genitourinary side effects have included urinary tract infection (5%). Albuminuria, cystitis, dysuria, hematuria, menstrual disorder, vaginal moniliasis, prostate disorder, and urinary frequency have also been reported.
Musculoskeletal side effects have included joint disorder (4% or greater), tenosynovitis (3%), synovitis (2%), arthralgia (1%), and leg cramps (1%). Arthrosis, bursitis, muscle cramps, myalgia, bone necrosis, bone pain, and tendon rupture have also been reported.
Metabolic side effects have included weight loss (4%) and hypokalemia (1%). Increased creatine phosphokinase, peripheral edema, hyperglycemia, and hyperlipidemia have also been reported.
Hypersensitivity side effects have included allergic reactions (2%). Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported rarely. At least one anaphylactic reaction has been reported following rechallenge of the drug after withdrawal due to rash. Erythema multiforme and vasculitis including cutaneous necrotizing vasculitis have been reported rarely in postmarketing experience. At least one case of hypersensitivity pneumonitis has also been reported.
A 69-year-old male with a 19-year history of rheumatoid arthritis experienced hypersensitivity pneumonitis coincident with leflunomide therapy. Three months after being administered leflunomide 20 mg once a day, he presented with a 1-month history of progressive dyspnea, decreased appetite, and weight loss. The temporal association and resolution following discontinuation suggest leflunomide was the causative agent.
The risk of pancytopenia appears to be increased when leflunomide (the active ingredient contained in Arava) is combined with methotrexate and in older patients.
Hematologic side effects have included anemia (including iron deficiency anemia), eosinophilia, and ecchymosis. Transient thrombocytopenia and leukopenia (less than 2000 G/L) have been reported rarely. Agranulocytosis, neutropenia, and pancytopenia have been reported rarely in postmarketing experience. At least 18 cases of pancytopenia have also been reported.
Endocrine side effects have included diabetes mellitus and hyperthyroidism.
Ocular side effects have included blurred vision, cataract, conjunctivitis, and eye disorder.
Renal side effects have not been reported but because of an effect on the brush border of the proximal renal tubule, leflunomide (the active ingredient contained in Arava) has a uricosuric effect. A separate effect of hypophosphatemia has also been reported. These effects have not been seen together, nor have there been alterations in renal function.
Oncologic side effects have been reported with some immunosuppressive medications. However, no increased risk for malignancy (primary lymphoproliferative disorders) have been reported in clinical trials with leflunomide (the active ingredient contained in Arava) Larger and longer-term studies are needed to determine whether there is an increased risk of malignancy or lymphoproliferative disorders with leflunomide.
A study reported an increased incidence in lymphoma in male mice. In the same study, an increased incidence of bronchoalveolar adenomas and carcinomas were reported in female mice. A minor metabolite of leflunomide, 4-trifluoromethylaniline (TFMA), was mutagenic in the Ames Assay and in the HGPRT Gene Mutation Assay and was clastogenic in the in vitro Assay for Chromosome Aberrations in Chinese Hamster Cells.
Hepatic side effects have included increased ALT level (greater than 5%), abnormal liver enzymes (5%), cirrhosis, and mild transaminitis. Hepatitis, jaundice/cholestasis, and severe liver injury, such as hepatic failure and acute hepatic necrosis that may be fatal, have been reported rarely in postmarketing experience. At least one case of liver tuberculosis has also been reported.
A 69-year-old male with stable rheumatoid arthritis experienced liver tuberculosis coincident with leflunomide therapy. The patient had been taking leflunomide 20 mg daily as monotherapy for 31 months. He presented with a 2 month history of anorexia, 10 kg weight loss, fever, and night sweats. A CT scan showed multiple low attenuation lesions in the liver. Initial liver biopsy was nondiagnostic, revealing only minor changes with no evidence of infection. Although Mycobacterium tuberculosis culture was negative, due to strong clinical suspicion, he was given empiric antituberculosis therapy. The patient's condition improved dramatically over subsequent weeks. At 18 months review, he remained well taking prednisone monotherapy. Although culture negative, a diagnosis of probable mycobacterium infection was made on the basis of typical histological findings on liver biopsy, exclusion of other pathology and prompt response to antituberculosis treatment.
Other side effects have included flu syndrome (greater than 5%), tiredness/lethargy (greater than 5%), injury (5%), accident (5%), infection (4%), asthenia (3%), abscess, cyst, fever, hernia, malaise, and taste perversion. Opportunistic infections and severe infections including sepsis that may be fatal have been reported rarely in postmarketing experience. At least one case of mycotic aneurysm has also been reported.
More Arava resources
- Arava Prescribing Information (FDA)
- Arava Consumer Overview
- Arava Monograph (AHFS DI)
- Arava MedFacts Consumer Leaflet (Wolters Kluwer)
- Arava Advanced Consumer (Micromedex) - Includes Dosage Information
- Leflunomide Prescribing Information (FDA)
- Leflunomide Professional Patient Advice (Wolters Kluwer)
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of information provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.